Richard M. Schultz

Richard M. Schultz has worked as a cancer researcher, drug development consultant, and medical writer for over 35 years. At Eli Lilly and Co., he was instrumental in the development of two blockbuster cancer drugs, Alimta and Gemzar. He is an internationally recognized expert on targeted cancer therapy and published a monograph on the subject: Advances in Targeted Cancer Therapy, Progress in Drug Research (R. M. Schultz, Ed.), 2005 Birkhauser Verlag, Basel (Switzerland). He has authored over 150 research papers in scientific books and prestigious journals, including Science and Nature and has presented over 100 lectures at national and international cancer meetings. Richard has written several medical review articles on the status of cancer treatment and on new drug discovery. He is an active member of the American Association for Cancer Research and has been an associate editor for Clinical Cancer Research.